New study shows how important CoQ10 really is

Steve - an October Journal of American College of Cardiology study was commissioned by the FDA to evaluate the importance of CoQ10 in clinical outcomes of 1,191 older subjects with heart failure taking rosuvastatin (Crestor) compared to placebo.

I'd say the importance of CoQ10 is evident after seeing these results.

• Patients in the lowest coenzyme Q10 concentration had more atrial fibrillation/flutter and had overall lower heart function compared with those with the highest concentration.

• After introducing medication, overall, coenzyme Q10 declined at 3 months with rosuvastatin but did not change in the placebo group (39% net difference).

• In patients treated with placebo, the risk of the pre-defined primary outcome of cardiovascular death, myocardial infarction, or stroke was numerically highest in patients in the lowest coenzyme Q10 tertile, intermediate in the middle tertile, and lowest in patients in the highest coenzyme Q10 tertile. The same relationship was seen between coenzyme Q10 tertile and mortality and hospitalizations.
  

• There was an excess of 11 deaths in the rosuvastatin group compared with placebo group.
  
  
• Looking at nonfatal events, there were 18 more patients hospitalized at least once for any reason in the rosuvastatin group compared with placebo group.
  
  
• There were 9 more nonfatal myocardial infarctions in the rosuvastatin group in the lowest coenzyme Q10 tertile.